Navigation Links
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Date:5/12/2008

ention estimate that between 20 and 50 percent of international travelers contract diarrhea. The effects go beyond the acute symptoms of the disease; between 10 and 30 percent of those who develop travelers' diarrhea will develop the chronic symptoms of irritable bowel syndrome.

Because of the extent of the problem and the lack of safe and effective prophylaxis, market studies suggest that there is a large market for an effective travelers' diarrhea vaccine, potentially exceeding USD 750 million annually. If approved, the Iomai vaccine would be the first vaccine for travelers' diarrhea available in the United States.

About Pandemic Influenza:

Three influenza pandemics have occurred in the 20th century leading to the death of more than 50 million people globally. By US government estimates, pandemic influenza has a greater potential to cause deaths and illnesses than virtually any other natural health threat. Signs of a pandemic influenza have emerged in Southeast Asia, as lethal infections of poultry and humans with avian influenza virus continue. The current virus is now endemic in bird populations, having spread to more than 40 countries and causing the deaths of hundreds of millions of birds. Furthermore, the World Health Organization reports that the number of avian flu cases in humans has reached more than 370 cases in 14 countries.

In November 2005, the US government announced a USD 7.1 billion initiative to prevent and prepare for a pandemic influenza outbreak. In January 2007, Iomai entered into a USD 128 million contract with the US government to develop a dose-sparing patch for use with a pandemic influenza vaccine.

About Japanese Encephalitis:

With over three billion people living in endemic areas, Japanese Encephalitis, a mosquito-borne flaviviral infection, is the leading cause of childhood encephalitis and viral encephalitis in Asia. The Japanese Encephalitis virus remains virulent in this region and has recent
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. U.S. Preventive Medicine Acquires Specialty Disease Management
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
8. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  The Academy of Managed ... Drug Administration,s (FDA,s) draft guidance and proposed rule ... biosimilars, to bear a nonproprietary name with an ... seeking a decision from the FDA on the ... care stakeholders urging the agency to use the ...
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate for ... proven, simple and effective palliative treatment of advanced prostate ... is the first and only six-month intramuscular (IM) GnRH ...
... the bio-pharmaceutical industry, new product commercialization efforts have taken on increased importance. It,s against this backdrop that new product planning ... , ... , ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 2Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 3Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 4
(Date:8/31/2015)... ... August 31, 2015 , ... All birth control methods work best ... lowest failure rates among birth control methods. Moreover, no-scalpel vasectomy has many proven advantages ... to have their vasectomy done because they are afraid of complications. , One ...
(Date:8/31/2015)... ... ... GenHart Software, LLC, a rising player in the software game headquartered in Charleston, ... cost effectively as possible, with a belief that the right software can solve any ... and the Charleston business community is taking notice. Just announced, The Harbor Entrepreneur ...
(Date:8/30/2015)... ... August 31, 2015 , ... Avid collector Andrew Hawley from Vintage Rock ... concert posters. This hand colored artwork is one of the most coveted Doors concert ... states, "When the doors played the Shrine, the band was one of the ...
(Date:8/30/2015)... ... August 31, 2015 , ... Intellitec Solutions, ... Convention & Expo October 5th & 6th in San Antonio, TX. Dedicated to ... brings industry professionals from all over the country come to share the latest ...
(Date:8/30/2015)... ... 30, 2015 , ... AvePoint, the established leader ... Silver Sponsor of the Digital Workplace Conference, taking place Sunday, August 30 – ... the event, AvePoint will showcase its file analysis, management, and migration solutions for ...
Breaking Medicine News(10 mins):Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4
... Baltimore has been chosen by The Gerontological Society of America ... honor, given annually, is a lectureship in geriatrics and is ... - both in research and practice - who is a ... presentation will take place at GSA,s 60th Annual Scientific Meeting, ...
... and ex-husband Kevin Federline continue to duke it out in ... A University of Missouri-Columbia researcher and expert in divorce and ... the damage that can be inflicted on children who are ... almost everything wrong, said Larry Ganong, professor and co-chair of ...
... Novartis Vaccines, in partnership with Public Health, - Seattle & King County and RediClinic, offers ... themselves and the many ... ... the 2006-2007 influenza season peaked in Seattle between mid ...
... for Women,s Health Research Report and Media Briefing ... WASHINGTON, Nov. 13 Women are more,susceptible ... as pregnancy, postpartum and perimenopause, according to a ... a Washington, D.C.-based,advocacy organization, released at a media ...
... enzyme, telomerase, is associated with the uncontrollable proliferation of ... all of human cancers. Since the mid-1990s, when telomerase ... the enzyme as an ideal target for developing broadly ... The Wistar Institute have brought this goal closer by ...
... out of ten people with diabetes are walking around ... problems that could lead to amputation, according to research ... of Clinical Practice. , Published to coincide with ... University of Dundee, has been welcomed by an expert ...
Cached Medicine News:Health News:Britney and K-Fed doing it all wrong, MU family researcher says 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 2Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 3Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 4Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 5Health News:Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 6Health News:Hormonal Changes and Depression: What is the Connection? 2Health News:Hormonal Changes and Depression: What is the Connection? 3Health News:Hormonal Changes and Depression: What is the Connection? 4Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 2Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 3Health News:63 percent of diabetics risk serious foot problems by wearing the wrong-sized shoes 2
Inquire...
Inquire...
... The compact Allegra X-22 Series is up to ... With a library of 11 rotors, the Allegra X-22 ... Features: Only 18 inches / 46 ... to 22,065 x g 3 different ways to ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: